Non-specific symptoms and post-treatment Lyme disease syndrome in patients with Lyme borreliosis: a prospective cohort study in Belgium (2016–2020) - BMC Infectious Diseases - BMC Infectious Diseases

Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, Hovius JWR, et al. Lyme borreliosis. Nat Rev Dis Primer. 2016;2:1–19.

Article  Google Scholar 

Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet. 2012;379:461–73.

Article  PubMed  Google Scholar 

Geebelen L, Van Cauteren D, Devleesschauwer B, Moreels S, Tersago K, Van Oyen H, et al. Combining primary care surveillance and a meta-analysis to estimate the incidence of the clinical manifestations of Lyme borreliosis in Belgium, 2015–2017. Ticks Tick-Borne Dis. 2019;10:598–605.

Article  PubMed  Google Scholar 

Cerar D, Cerar T, Ruzic-Sabljic E, Wormser GP, Strle F. Subjective symptoms after treatment of early Lyme disease. AmJMed. 2010;123:79–86.

Google Scholar 

Stupica D, Lusa L, Ruzić-Sabljić E, Cerar T, Strle F. Treatment of erythema migrans with doxycycline for 10 days versus 15 days. Clin Infect Dis. 2012;55:343–50.

Article  CAS  PubMed  Google Scholar 

Stupica D, Maraspin V, Bogovic P, Ogrinc K, Blagus R, Cerar T, et al. Comparison of clinical course and treatment outcome for patients with early disseminated or early localized Lyme borreliosis. JAMA Dermatol. 2018;154:1050–6.

Article  PubMed  Google Scholar 

Nowakowski J, Nadelman RB, Sell R, McKenna D, Cavaliere LF, Holmgren D, et al. Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med. 2003;115:91–6.

Article  PubMed  Google Scholar 

Weitzner E, McKenna D, Nowakowski J, Scavarda C, Dornbush R, Bittker S, et al. Long-term assessment of post-treatment symptoms in patients with culture-confirmed early Lyme disease. Clin Infect Dis. 2015;61:1800–6.

Article  PubMed  PubMed Central  Google Scholar 

Wormser GP, Ramanathan R, Nowakowski J, McKenna D, Holmgren D, Visintainer P, et al. Duration of antibiotic therapy for early Lyme disease. Ann Intern Med. 2003;138:697–704.

Article  CAS  PubMed  Google Scholar 

Sjöwall J, Fryland L, Nordberg M, Sjögren F, Garpmo U, Jansson C, et al. Decreased Th1-type inflammatory cytokine expression in the skin is associated with persisting symptoms after treatment of erythema migrans. PLoS ONE. 2011;6: e18220.

Article  PubMed  PubMed Central  Google Scholar 

Aucott JN, Rebman AW, Crowder LA, Kortte KB. Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here? Qual Life Res. 2013;22:75–84.

Article  PubMed  Google Scholar 

Koedel U, Fingerle V, Pfister HW. Lyme neuroborreliosis-epidemiology, diagnosis and management. Nat Rev Neurol. 2015;11:446–56.

Article  PubMed  Google Scholar 

Dersch R, Sommer H, Rauer S, Meerpohl JJ. Prevalence and spectrum of residual symptoms in Lyme neuroborreliosis after pharmacological treatment: a systematic review. J Neurol. 2016;263:17–24.

Article  CAS  PubMed  Google Scholar 

Ljøstad U, Mygland Å. Remaining complaints 1 year after treatment for acute Lyme neuroborreliosis; frequency, pattern and risk factors. Eur J Neurol. 2010;17:118–23.

Article  PubMed  Google Scholar 

Eikeland R, Mygland A, Herlofson K, Ljostad U. European neuroborreliosis: quality of life 30 months after treatment. Acta Neurol Scand. 2011;124:349–54.

Article  CAS  PubMed  Google Scholar 

Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43:1089–134.

Article  PubMed  Google Scholar 

Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001;345:85–92.

Article  CAS  PubMed  Google Scholar 

Berende A, ter Hofstede HJM, Vos FJ, van Middendorp H, Vogelaar ML, Tromp M, et al. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. Engl J Med. 2016. https://doi.org/10.1056/NEJMoa1505425.

Article  Google Scholar 

Krupp LB, Hyman LG, Grimson R, Coyle PK, Melville P, Ahnn S, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology. 2003;60:1923–30.

Article  CAS  PubMed  Google Scholar 

Cameron DJ. Consequences of treatment delay in Lyme disease. J Eval Clin Pract. 2007;13:470–2.

Article  PubMed  Google Scholar 

Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. 2008;70:992–1003.

Article  CAS  PubMed  Google Scholar 

Geebelen L, Lernout T, Kabamba-Mukadi B, Saegeman V, Sprong H, Van Gucht S, et al. The HUMTICK study: protocol for a prospective cohort study on post-treatment Lyme disease syndrome and the disease and cost burden of Lyme borreliosis in Belgium. Arch Public Health. 2017;75:42.

Article  PubMed  PubMed Central  Google Scholar 

Stanek G, Fingerle V, Hunfeld K-P, Jaulhac B, Kaiser R, Krause A, et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect. 2011;17:69–79.

Article  CAS  PubMed  Google Scholar 

Centers for Disease Control and Prevention. Lyme disease (Borrelia burgdorferi) 2011 case definition.

Nemeth J, Bernasconi E, Heininger U, Abbas M, Nadal D, Strahm C, et al. Update of the Swiss guidelines on post-treatment Lyme disease syndrome. Swiss Med Wkly. 2016;146: w14353.

PubMed  Google Scholar 

Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.

Article  PubMed  Google Scholar 

Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, et al. Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations. J Clin Epidemiol. 1998;51:1055–68.

Article  CAS  PubMed  Google Scholar 

Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The cognitive failures questionnaire (CFQ) and its correlates. Br J Clin Psychol. 1982;21(Pt 1):1–16.

Article  CAS  PubMed  Google Scholar 

Robine JM, Jagger C. Creating a coherent set of indicators to monitor health across Europe: the Euro-REVES 2 project. Eur J Public Health. 2003;13(3 Suppl):6–14.

Article  PubMed  Google Scholar 

Van OH, Van der Heyden J, Perenboom R, Jagger C. Monitoring population disability: evaluation of a new global activity limitation indicator (GALI). Soz Praventivmed. 2006;51:153–61.

Article  Google Scholar 

Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22:1717–27.

Article  CAS  PubMed  Google Scholar 

R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018. https://www.R-project.org/. Accessed 24 Feb 2020.

van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1–67.

Article  Google Scholar 

Bechtold KT, Rebman AW, Crowder LA, Johnson-Greene D, Aucott JN. Standardized symptom measurement of individuals with early Lyme disease over time. Arch Clin Neuropsychol. 2017;32:129–41.

Article  PubMed  Google Scholar 

Wormser GP, McKenna D, Karmen CL, Shaffer KD, Silverman JH, Nowakowski J, et al. Prospective evaluation of the frequency and severity of symptoms in lyme disease patients with erythema migrans compared with matched controls at baseline, 6 months, and 12 months. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciz1215.

Article  PubMed  PubMed Central  Google Scholar 

Ursinus J, Vrijmoeth HD, Harms MG, Tulen AD, Knoop H, Gauw SA, et al. Prevalence of persistent symptoms after treatment for lyme borreliosis: a prospective observational cohort study. Lancet Reg Health Eur. 2021;6: 100142.

Article  PubMed  PubMed Central  Google Scholar 

Mac S, Bahia S, Simbulan F, Pullenayegum EM, Evans GA, Patel SN, et al. Long-term sequelae and health-related quality of life associated with Lyme disease: a systematic review. Clin Infect Dis. 2020;71:440–52.

Article  PubMed  Google Scholar 

Aucott JN, Crowder LA, Kortte KB. Development of a foundation for a case definition of post-treatment Lyme disease syndrome. Int J Infect Dis. 2013;17:e443–9.

Article  PubMed  Google Scholar 

Aucott JN. Posttreatment Lyme disease syndrome. Infect Dis Clin N Am. 2015;29:309–23.

Article  Google Scholar 

Rebman AW, Aucott JN. Post-treatment Lyme disease as a model for persistent symptoms in Lyme disease. Front Med. 2020;7:57.

Article  Google Scholar 

Eliassen KE, Hjetland R, Reiso H, Lindbæk M, Tschudi-Madsen H. Symptom load and general function among patients with erythema migrans: a prospective study with a 1-year follow-up after antibiotic treatment in Norwegian general practice. Scand J Prim Health Care. 2017;35:75–83.

Article  PubMed  PubMed Central  Google Scholar 

Lantos PM, Rumbaugh J, Bockenstedt LK, Falck-Ytter YT, Aguero-Rosenfeld ME, Auwaerter PG, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis, and treatment of Lyme disease. Arthritis Rheumatol. 2021;73:12–20.

Article  PubMed  Google Scholar 

Kalish RA, Kaplan RF, Taylor E, Jones-Woodward L, Workman K, Steere AC. Evaluation of study patients with Lyme disease, 10–20-year follow-up. J Infect Dis. 2001;183:453–60.

Article  CAS  PubMed  Google Scholar 

Shadick NA, Phillips CB, Sangha O, Logigian EL, Kaplan RF, Wright EA, et al. Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease. Ann Intern Med. 1999;131:919–26.

Article  CAS  PubMed  Google Scholar 

Moon KA, Pollak J, Hirsch AG, Aucott JN, Nordberg C, Heaney CD, et al. Epidemiology of Lyme disease in Pennsylvania 2006–2014 using electronic health records. Ticks Tick-Borne Dis. 2019;10:241–50.

Article  PubMed  Google Scholar 

Wills AB, Spaulding AB, Adjemian J, Prevots DR, Turk S-P, Williams C, et al. Long-term follow-up of patients with Lyme disease: longitudinal analysis of clinical and quality-of-life measures. Clin Infect Dis. 2016;62:1546–51.

Article  PubMed  PubMed Central  Google Scholar 

Boršič K, Blagus R, Cerar T, Strle F, Stupica D. Clinical course, serologic response, and long-term outcome in elderly patients with early Lyme borreliosis. J Clin Med. 2018;7:506.

Article  PubMed Central  Google Scholar 

Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333:575.

Article  PubMed  PubMed Central  Google Scholar 

Lancet T. Facing up to long COVID. Lancet. 2020;396:1861.

Article  Google Scholar 

Belgian Antibiotic Policy Coordination Committee (BAPCOC). Recommandations: borréliose de Lyme 2017. 2017.

Gelman A, Carlin J. Beyond power calculations: assessing type S (sign) and type M (magnitude) errors. Perspect Psychol Sci. 2014;9:641–51.

Article  PubMed  Google Scholar 

Adblock test (Why?)